187 related articles for article (PubMed ID: 36613510)
21. Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells.
Duarte D; Rêma A; Amorim I; Vale N
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204691
[TBL] [Abstract][Full Text] [Related]
22. Comparison between CoFactor and Leucovorin activity applied in combination with 5-fluorouracil against two human colon cancer cell lines.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2007; 12(1):71-6. PubMed ID: 17436405
[TBL] [Abstract][Full Text] [Related]
23. L-Canavanine Potentiates Cytotoxicity of Chemotherapeutic Drugs in Human Breast Cancer Cells.
Nurcahyanti AD; Wink M
Anticancer Agents Med Chem; 2017; 17(2):206-211. PubMed ID: 26902604
[TBL] [Abstract][Full Text] [Related]
24. Conditionally replicative adenovirus-based mda-7/IL-24 expression enhances sensitivity of colon cancer cells to 5-fluorouracil and doxorubicin.
Xu J; Mo Y; Wang X; Liu J; Zhang X; Wang J; Hu L; Yang C; Chen L; Wang Y
J Gastroenterol; 2013 Feb; 48(2):203-13. PubMed ID: 22820863
[TBL] [Abstract][Full Text] [Related]
25. Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment.
Duong HH; Yung LY
Int J Pharm; 2013 Sep; 454(1):486-95. PubMed ID: 23792465
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
Holmes FA
Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
[TBL] [Abstract][Full Text] [Related]
27. Colossolactone-G synergizes the anticancer properties of 5-fluorouracil and gemcitabine against colorectal cancer cells.
Algehani RA; Abou Khouzam R; Hegazy GA; Alamoudi AA; El-Halawany AM; El Dine RS; Ajabnoor GA; Al-Abbasi FA; Baghdadi MA; Elsayed I; Hattori M; Al-Abd AM
Biomed Pharmacother; 2021 Aug; 140():111730. PubMed ID: 34062410
[TBL] [Abstract][Full Text] [Related]
28. Synergistic cytotoxic effects of inorganic phosphate and chemotherapeutic drugs on human osteosarcoma cells.
Spina A; Sorvillo L; Chiosi E; Esposito A; Di Maiolo F; Sapio L; Caraglia M; Naviglio S
Oncol Rep; 2013 May; 29(5):1689-96. PubMed ID: 23446517
[TBL] [Abstract][Full Text] [Related]
29. Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer.
Tong J; Xie G; He J; Li J; Pan F; Liang H
J Biomed Biotechnol; 2011; 2011():740564. PubMed ID: 21403907
[TBL] [Abstract][Full Text] [Related]
30. Novel Strategies for Cancer Combat: Drug Combination Using Repurposed Drugs Induces Synergistic Growth Inhibition of MCF-7 Breast and HT-29 Colon Cancer Cells.
Duarte D; Guerreiro I; Vale N
Curr Issues Mol Biol; 2022 Oct; 44(10):4930-4949. PubMed ID: 36286050
[TBL] [Abstract][Full Text] [Related]
31. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines.
Zoli W; Ulivi P; Tesei A; Fabbri F; Rosetti M; Maltoni R; Giunchi DC; Ricotti L; Brigliadori G; Vannini I; Amadori D
Breast Cancer Res; 2005; 7(5):R681-9. PubMed ID: 16168113
[TBL] [Abstract][Full Text] [Related]
32. Frondoside A Enhances the Anti-Cancer Effects of Oxaliplatin and 5-Fluorouracil on Colon Cancer Cells.
Attoub S; Arafat K; Khalaf T; Sulaiman S; Iratni R
Nutrients; 2018 May; 10(5):. PubMed ID: 29724012
[TBL] [Abstract][Full Text] [Related]
33. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment.
Pasquier E; Ciccolini J; Carre M; Giacometti S; Fanciullino R; Pouchy C; Montero MP; Serdjebi C; Kavallaris M; André N
Oncotarget; 2011 Oct; 2(10):797-809. PubMed ID: 22006582
[TBL] [Abstract][Full Text] [Related]
34. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells.
Sasaki K; Tsuno NH; Sunami E; Tsurita G; Kawai K; Okaji Y; Nishikawa T; Shuno Y; Hongo K; Hiyoshi M; Kaneko M; Kitayama J; Takahashi K; Nagawa H
BMC Cancer; 2010 Jul; 10():370. PubMed ID: 20630104
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer.
Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
Biochem Biophys Res Commun; 2018 Sep; 503(4):2286-2292. PubMed ID: 29959920
[TBL] [Abstract][Full Text] [Related]
36. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer.
Wu L; Wang W; Tian J; Qi C; Cai Z; Yan W; Xuan S; Shang A
Bioengineered; 2022 Jan; 13(1):1942-1951. PubMed ID: 35019820
[TBL] [Abstract][Full Text] [Related]
38. Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
Kurebayashi J; Nukatsuka M; Sonoo H; Uchida J; Kiniwa M
Cancer Chemother Pharmacol; 2010 Jan; 65(2):219-25. PubMed ID: 19455332
[TBL] [Abstract][Full Text] [Related]
39. The development of peptide-drug conjugates (PDCs) strategies for paclitaxel.
Wang L; Chen H; Wang F; Zhang X
Expert Opin Drug Deliv; 2022 Feb; 19(2):147-161. PubMed ID: 35130795
[TBL] [Abstract][Full Text] [Related]
40. Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer.
Roque MC; Franco MS; Vilela JMC; Andrade MS; de Barros ALB; Leite EA; Oliveira MC
Curr Drug Deliv; 2019; 16(9):829-838. PubMed ID: 31622204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
